Cargando…

New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis

Atopic dermatitis (AD) is a chronic cutaneous inflammatory disorder, characterized by skin barrier disruption. Dermacare is a new cosmetic formulation, which enhances moisturization, reinforces and repairs the skin barrier, and prevents cutaneous microbiota imbalance. To demonstrate its safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Lucas, Raúl, García-Millán, Cristina, Pérez-Davó, Azahara, Moreno, Esther, Redondo, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406490/ https://www.ncbi.nlm.nih.gov/pubmed/30700045 http://dx.doi.org/10.3390/children6020017

Ejemplares similares

Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020)

Current Perspectives on the Management of Infantile Atopic Dermatitis
por: Davari, Danielle R, et al.
Publicado: (2020)

Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis
por: Seghers, Amelie Clementine, et al.
Publicado: (2014)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Paediatric atopic eczema (atopic dermatitis) in South Africa: A practical algorithm for the management of mild-to-moderate disease in daily clinical practice
por: Kannenberg, Susanna M., et al.
Publicado: (2020)

Infantile atopic dermatitis and maternal-infant bonding: a mixed methods study
por: Batac, Ayel Luis R., et al.
Publicado: (2023)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

Tolerability and Efficacy of a Medical Device Repairing Emollient Cream in Children and Adults with Mild to Moderate Atopic Dermatitis
por: Pinter, Andreas, et al.
Publicado: (2019)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Medihoney Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children: An Open-Label Randomized Pilot Study
por: Horev, Amir, et al.
Publicado: (2022)

Prediction of disease severity using serum biomarkers in patients with mild-moderate Atopic Dermatitis: A pilot study
por: Lee, In-Seon, et al.
Publicado: (2023)

Evaluation of the Efficacy of an Ecobiological Dermo-Cosmetic Product to Help Manage and Prevent Relapses of Eyelid Atopic Dermatitis
por: Bergera-Virassamynaïk, Sandrine, et al.
Publicado: (2023)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case–Control Study
por: Toron, Farah, et al.
Publicado: (2021)

Allergic diseases of the skin and drug allergies – 2018. Risk factors for hypoproteinemia in infantile atopic dermatitis
por: Park, Geunhwa
Publicado: (2013)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

The diagnosis of cosmetic contact dermatitis: a study using standard, cosmetic, and hair cosmetic batteries
por: Bevilaqua, Mariele, et al.
Publicado: (2019)

Identification of Molecular Signatures in Mild Intrinsic Atopic Dermatitis by Bioinformatics Analysis
por: Yin, Huibin, et al.
Publicado: (2020)

Establishment and Characterization of Mild Atopic Dermatitis in the DNCB-Induced Mouse Model
por: Riedl, Rebecca, et al.
Publicado: (2023)

Biological Treatments in Atopic Dermatitis
por: Montes-Torres, Andrea, et al.
Publicado: (2015)

Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey
por: Sastre, Joaquín, et al.
Publicado: (2020)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Formulation and clinical evaluation of silymarin pluronic-lecithin organogels for treatment of atopic dermatitis
por: Mady, Fatma M, et al.
Publicado: (2016)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial
por: Niemeyer‐van der Kolk, Tessa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t6vb9pdmqrqmp2uc9b4l302mju